Eighty-five percent of diagnosed cases of lung cancer are non-small cell lung cancer (NSCLC). In this group, 5% of patients ...

From new KRAS and HER2 inhibitors to home-administered immunotherapy, recent trials mark a turning point in how metastatic lung cancer is managed.

If you have metastatic non-small-cell lung cancer (NSCLC), you might wonder if the treatment plan that your doctor recommended is the best one for you. Metastatic NSCLC is “stage IV” or ...

This paper explores the potential of mitochondrial-associated programmed-cell-death (mtPCD) patterns as biomarkers for ...

Lung cancer is the leading cause of cancer-related deaths in the United States, with NSCLC accounting for up to 85% of diagnoses. While surgery has been a primary treatment option for some early ...

Savolitinib plus osimertinib may be a chemotherapy-free treatment option for patients with EGFR-mutant, advanced NSCLC with MET overexpression/amplification whose disease has progressed on osimertinib ...

Tagrisso is associated with positive outcomes among patients with unresectable stage 3 EGFR-mutant non-small cell lung cancer ...

LaunXP will take the lead on developing the therapy and EGFRi combo for NSCLC treatment within its designated territories. Apollomics CEO Dr Guo-Liang Yu stated: “We are delighted to partner ...

There are different treatment options available to target the NSCLC and help alleviate symptoms. Talk with your doctor to see which are best for you.

First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for ImmutepGlobal Phase III with ...